Media Mentions
2008
Tim Bryant was quoted in an August 20 article published by Reuters regarding the increase in private equity funds specializing in health care royalty financing as a result of companies finding a new way to hedge risk and raise capital. Mr. Bryant commented on the increased amount of royalties for sale as well as the increased interest from investors in royalties as a way to get stable returns in a volatile market. "Large pools of capital have become interested in these investments because they do not correlate to the traditional debt and equity markets. This is a huge market and we are only at the early stages of its development," he said.
Timothy R.M. Bryant, Corporate, Healthcare Royalty Sales, Life Sciences & Medical Devices
2007
Tim Bryant was quoted in the September 07 issue of Private Equity Europe regarding the failed attempt to draw private equity interest on the buy-out side of pharmaceuticals due to the high emphasis on R&D costs. Unlike healthcare providers, income from drug development are less visible and the model is more complex. "Historically, drug development has been a cyclical business, driven by blockbuster drug development. Growth and cashflow is uncertain," Mr. Bryant said.
